| GTO ID | GTC3189 |
| Trial ID |
NCT05552326
|
| Disease |
Severe Hypertriglyceridemia
|
| Altered gene | APOC3 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | Olezarsen|ISIS 678354|IONIS-APOCIII-LRx|AKCEA-APOCIII-LRx |
| Co-treatment | Clopidogrel |
| Phase | Phase3 |
| Recruitment status | Active, Not Recruiting |
| Title | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia |
| Year | 2022 |
| Country | Argentina|Belgium|Brazil|Bulgaria|Canada|Czechia|France|Greece|Hungary|India|Italy|Lithuania|Malaysia|Mexico|Netherlands|Poland|Portugal|Romania|Slovakia|Spain|Sweden|China|United States |
| Company sponsor | Ionis Pharmaceuticals, Inc. |
| Other ID(s) | ISIS 678354-CS6|2022-501420-20 |